Functional Genomics for Cancer Drug Target Discovery

被引：47
|
作者：
Haley, Benjamin [1 ]
Roudnicky, Filip [2 ]
机构：
[1] Genentech Inc, Mol Biol Dept, 1 DNA Way, San Francisco, CA 94080 USA
[2] F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Pharmaceut Res & Early Dev, CH-4070 Basel, Switzerland
来源：
CANCER CELL | 2020年 / 38卷 / 01期
关键词：
LARGE-SCALE; SYNTHETIC LETHALITY; CRISPR-CAS9; SCREENS; GENE ESSENTIALITY; RNAI; SHRNA; GUIDE; IDENTIFICATION; CRISPR/CAS9; MUTAGENESIS;
D O I：
10.1016/j.ccell.2020.04.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Functional genomics describes a field of biology that uses a range of approaches for assessing gene function with high-throughput molecular, genetic, and cellular technologies. The near limitless potential for applying these concepts to study the activities of all genetic loci has completely upended how today's cancer biologists tackle drug target discovery. We provide an overview of contemporary functional genomics platforms, highlighting areas of distinction and complementarity across technologies, so as to aid in the development or interpretation of cancer-focused screening efforts.
引用
收藏
页码：31 / 43
页数：13
相关论文
共 50 条
  • [31] CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer
    Tsujino, Takuya
    Komura, Kazumasa
    Inamoto, Teruo
    Azuma, Haruhito
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)
  • [32] HTS and hit finding in academia - from chemical genomics to drug discovery
    Frearson, Julie A.
    Collie, Iain T.
    DRUG DISCOVERY TODAY, 2009, 14 (23-24) : 1150 - 1158
  • [33] Genomics in drug discovery: The best things come to those who wait
    Bansal, Aruna T.
    Barnes, Michael R.
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2008, 11 (03) : 303 - 310
  • [34] In Vivo Cancer-Based Functional Genomics
    Li, Chennan
    Kasinski, Andrea L.
    TRENDS IN CANCER, 2020, 6 (12): : 1002 - 1017
  • [35] Functional genomics to explore cancer cell vulnerabilities
    Kahle, Kristopher T.
    Kozono, David
    Ng, Kimberly
    Hsieh, Grace
    Zinn, Pascal O.
    Nitta, Masayuki
    Chen, Clark C.
    NEUROSURGICAL FOCUS, 2010, 28 (01) : E5.1 - E5.7
  • [36] Emerging target discovery and drug repurposing opportunities in chordoma
    Freed, Daniel M.
    Sommer, Josh
    Punturi, Nindo
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [37] Bromodomain Factor 5 as a Target for Antileishmanial Drug Discovery
    Russell, Catherine N.
    Carter, Jennifer L.
    Borgia, Juliet M.
    Bush, Jacob
    Calderon, Felix
    Gabarro, Raquel
    Conway, Stuart J.
    Mottram, Jeremy C.
    Wilkinson, Anthony J.
    Jones, Nathaniel G.
    ACS INFECTIOUS DISEASES, 2023, 9 (11): : 2340 - 2357
  • [38] Alternative splicing as a biomarker and potential target for drug discovery
    Le, Kai-qin
    Prabhakar, Bellur S.
    Hong, Wan-jin
    Li, Liang-cheng
    ACTA PHARMACOLOGICA SINICA, 2015, 36 (10) : 1212 - 1218
  • [39] Drug mechanism-of-action discovery through the integration of pharmacological andCRISPRscreens
    Goncalves, Emanuel
    Segura-Cabrera, Aldo
    Pacini, Clare
    Picco, Gabriele
    Behan, Fiona M.
    Jaaks, Patricia
    Coker, Elizabeth A.
    van der Meer, Donny
    Barthorpe, Andrew
    Lightfoot, Howard
    Mironenko, Tatiana
    Beck, Alexandra
    Richardson, Laura
    Yang, Wanjuan
    Lleshi, Ermira
    Hall, James
    Tolley, Charlotte
    Hall, Caitlin
    Mali, Iman
    Thomas, Frances
    Morris, James
    Leach, Andrew R.
    Lynch, James T.
    Sidders, Ben
    Crafter, Claire
    Iorio, Francesco
    Fawell, Stephen
    Garnett, Mathew J.
    MOLECULAR SYSTEMS BIOLOGY, 2020, 16 (07)
  • [40] Potential Drug Target Discovery Based on Bioinformatics Methods
    Liu Wei
    Xie Hong-Wei
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2011, 38 (01) : 11 - 19
12345